Početna › Kronična mijelomonocitna leukemija
Kliničke studije za Kronična mijelomonocitna leukemija koje traže sudionike u SAD-u
42 studija za Kronična mijelomonocitna leukemija traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Houston, TX16 studija
- Seattle, WA10 studija
- Boston, MA7 studija
- Baldwin Park, CA6 studija
- New York City, NY6 studija
- Mountain View, CA6 studija
- Rochester, MN6 studija
- Durham, NC5 studija
- Birmingham, AL4 studija
- Miami, FL4 studija
- Atlanta, GA4 studija
- Tampa, FL4 studija
- Columbus, OH4 studija
- Portland, OR3 studija
- Charleston, SC3 studija
- Los Angeles, CA3 studija
- Nashville, TN3 studija
Po državama
- Alabama4 studija
- Florida8 studija
- Georgia4 studija
- Kalifornija12 studija
- Maryland3 studija
- Massachusetts7 studija
- Minnesota7 studija
- New York8 studija
- North Carolina5 studija
- Ohio5 studija
- Oregon3 studija
- Pennsylvania4 studija
- South Carolina3 studija
- Tennessee3 studija
- Texas18 studija
- Washington10 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
U tijeku regrutacijaFaza 1
Od 18 do 120 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06904066Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT03418038CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT04375631(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
U tijeku regrutacijaFaza 2Zdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT03383575Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT07249346Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 27. kol 2026. · NCT06523556Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT07033598TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
U tijeku regrutacijaFaza 1
Od 18 do 80 godina · Oba spola · Ažurirano 17. kol 2026. · NCT07302776Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 12. kol 2026. · NCT07143669Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
U tijeku regrutacijaFaza 2/3Zdravi dobrovoljci dobrodošli
Od 18 do 70 godina · Oba spola · Ažurirano 11. kol 2026. · NCT04708054Pacritinib in CMML
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 11. kol 2026. · NCT06159491Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
U tijeku regrutacijaFaza 1/2
Od 12 do 80 godina · Oba spola · Ažurirano 7. kol 2026. · NCT05092451Personalized NK Cell Therapy in CBT
U tijeku regrutacijaFaza 2
Od 15 do 80 godina · Oba spola · Ažurirano 30. srp 2026. · NCT02727803Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 20. srp 2026. · NCT07046078Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 15. srp 2026. · NCT07128381Registry of Older Patients With Cancer
U tijeku regrutacijaOpažajna studija
Od 65 godina i više · Oba spola · Ažurirano 29. lip 2026. · NCT01137825Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 29. lip 2026. · NCT06815003211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
U tijeku regrutacijaFaza 1/2
Od 18 do 75 godina · Oba spola · Ažurirano 22. lip 2026. · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
U tijeku regrutacijaFaza 1/2
Od 18 do 75 godina · Oba spola · Ažurirano 22. lip 2026. · NCT03670966Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. lip 2026. · NCT05549661Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
U tijeku regrutacijaRana faza 1
Od 18 do 75 godina · Oba spola · Ažurirano 3. lip 2026. · NCT03964506Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
U tijeku regrutacijaFaza 2Zdravi dobrovoljci dobrodošli
6 Months · Oba spola · Ažurirano 29. svi 2026. · NCT04195633Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.